HATS 2001

1 Treatments

Studied treatment  simvastatin plus niacin

Control treatment  placebo

Concomitant treatments  -

Male (%)  13%
Age (years)  53 y

2 Patients

Patients  patients with coronary disease, low HDL cholesterol levels and normal LDL cholesterol levels

Inclusion criteria  clinical coronary disease (defined as previous myocardial infarction, coronary interventions, or confirmed angina) and with at least three stenoses of at least 30 percent of the luminal diameter or one stenosis of at least 50 percent; low levels of HDL cholesterol (35 mg per deciliter [0.91 mmol per liter] or lower in men and 40 mg per deciliter [1.03 mmol per liter] in women), LDL cholesterol levels of 145 mg per deciliter (3.75 mmol per liter) or lower, and triglyceride levels below 400 mg per deciliter (4.52 mmol per liter)

Exclusion criteria  -

Diabetes (%)  16%

History of CHD  55% history of MI

3 Methods

Blinding  double blind

Design  Factorial plan

Centers  2

Geographical area  USA, Canada

Sizes  73/73
4 Results

<table>
<thead>
<tr>
<th>Endpoint</th>
<th>T1</th>
<th>T0</th>
<th>d</th>
<th>95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>coronary death</td>
<td>-/73</td>
<td>-/73</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>all-cause death</td>
<td>1/80</td>
<td>1/80</td>
<td>1,00</td>
<td>[0,06; 16,27]</td>
</tr>
<tr>
<td>stroke</td>
<td>0/38</td>
<td>2/38</td>
<td>0,20</td>
<td>[0,01; 4,31]</td>
</tr>
<tr>
<td>cardiovascular events</td>
<td>4/80</td>
<td>10/80</td>
<td>0,43</td>
<td>[0,14; 1,36]</td>
</tr>
<tr>
<td>major CHD events</td>
<td>1/38</td>
<td>5/38</td>
<td>0,27</td>
<td>[0,04; 1,76]</td>
</tr>
<tr>
<td>cardiovascular deaths</td>
<td>1/80</td>
<td>1/80</td>
<td>1,00</td>
<td>[0,10; 9,82]</td>
</tr>
</tbody>
</table>

5 References